HL7 Europe is one of 73 organizations participating in the READi project with partners across 18 countries to work towards enhancing Patient Representativeness and Inclusion in Clinical Research. HL7 will participate in standards alignment and interoperability as well as communication, sustainability, and stakeholder engagement. READi Consortium press release
The goals of this 6-year IHI JU project is to enhance the representativeness of underserved (US) and underrepresented (UR) populations in clinical studies by fostering a more cohesive and integrated clinical study ecosystem.
READI will help US/UR communities overcome barriers to clinical study participation, such as lack of information or awareness, mistrust, poor communication, geographic limitations, and prejudice. In turn, this will enhance research on many diseases and conditions, improve preventative care and treatment effectiveness across diverse demographic groups, and better serve society.
HL7 Europe will engage in Work Packages 2 and 9:
- WP 2 – Platform Architecture & Implementation of Digital Platform. Specifically, ensuring HL7® FHIR® alignment, interoperability with other standards across initiatives.
- WP 9 – Communication, Sustainability and Stakeholder Engagement.
#HealthEquity #ClinicalResearch #IHI#innovation #READI #HL7 Europe
For more information visit the READi website.
This project is supported by the Innovative Health Initiative Joint Undertaking (IHI JU) under grant agreement No 101166227.The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bío, MedTech Europe, Vaccines Europe and Medicines and Healthcare Products Regulatory Agency and Breakthtough T1D. UKRI UK Research and Innovation also supports this project.